The funding round was led by new investor Ackermans & van Haaren and included other new investors like Driehaus Capital Management and Quest for Growth. Existing investors such as BioGeneration Ventures and Capricorn Health-tech Fund also continued their support. The additional funding will support early-stage clinical trials for two of their drug programmes and help advance two more programmes towards approval.
About Confo Therapeutics
Confo Therapeutics is a clinical-stage biotechnology company committed to identifying and accelerating novel medicines targeting GPCRs (G protein-coupled receptors). The company’s mission is being advanced by a team of highly experienced industry experts with extensive knowledge of the discovery and development of GPCR-directed medicines. Confo Therapeutics is headquartered in Ghent, Belgium.
Press release
- Confotherapeutics.com: Confo Therapeutics announces EUR 60M Series B financing to advance a pipeline of novel GPCR-modulating therapies into clinical development